To determine the in vitro stability of endogenous and recombinant erythropoietin (EPO) incubated at 371C in amniotic fluid (AF) and fetal plasma.
INTRODUCTION
Erythropoietin (EPO) is the primary regulator of fetal erythropoiesis and, when present in abnormally elevated concentrations, is a useful marker of fetal distress and chronic hypoxia. 1, 2 As such, EPO may provide important information to clinicians following an unexpected fetal loss. 3 EPO is primarily produced in the liver prenatally and the kidney postnatally. As there is no transplacental exchange of EPO in the human, 4 hormone concentrations obtained from amniotic fluid (AF) and fetal plasma reflect fetal production.
Endogenous EPO levels obtained at delivery following normal, uncomplicated pregnancies range from 1.07 to 19.1 mU/ml in AF, 1, 5 and from 10 to 60 mU/ml in fetal serum. 2 In animal models in vivo, EPO levels increase in response to hypoxemia, with elevated levels demonstrated within 3 hours in serum and 9 hours in AF. 6 Serial AF EPO data also exist in humans. There is one report showing a rise in AF EPO after 6 hours of labor in normal women and in women engaging in regular exercise throughout pregnancy. 7 AF EPO levels have been useful in distinguishing between acute and chronic causes of intrauterine demise, with abnormally elevated levels associated with chronic hypoxia preceding demise. 2, 3, 8 Historically, investigators evaluating markedly elevated EPO levels in AF after fetal demise postulated that EPO levels did not decline following demise, or declined very slowly. 2, 9 While EPO has been shown to be stable when incubated in vitro in plasma at room temperature, 10, 11 its stability at body temperature has not been reported. Teramo and co-workers 2 examined the in vitro stability of endogenous EPO in five samples of AF at 371C and showed that less than 50% of the initial EPO concentration remained after 21 days. These limited data warrant further study to more fully characterize the rate of EPO degradation in both AF and plasma in order to estimate the EPO concentration likely to have been present at the time of fetal demise.
The purpose of this study was to determine the in vitro stability of endogenous EPO in human AF and fetal plasma during incubation at 371C over 21 days. We hypothesized that degradative properties of AF and plasma would cause a significant decline in endogenous and recombinant EPO levels not observed in buffer. We also hypothesized that rHuEPO would be degraded less rapidly than endogenous EPO in AF and plasma, as has been suggested by other studies comparing modified EPOs.
METHODS
AF and fetal cord blood from normal and high-risk pregnancies resulting in live-born infants were selected for study. The latter included those affected by intrauterine growth restriction, fetal distress, or maternal infection, all conditions associated with elevated EPO levels. 1, 13, 14 The Institutional Review Board of the University of Iowa Hospitals and Clinics and The Ethical Committee of the Department of Obstetrics and Gynecology, University Central Hospital, Helsinki, Finland approved the study.
Plasma was isolated from cord blood via centrifugation, and all samples were stored at À201C until study. Endogenous EPO levels were measured in each sample prior to incubation. In all, 17 fluid samples (nine AF and eight plasma) with low normal endogenous EPO were spiked with recombinant human EPO (rHuEPO) for comparison of recombinant and endogenous EPO stability. Our purpose for doing this was to evaluate the stability of rHuEPO at 371C in plasma and AF. The amount of rHuEPO added was typically 10-fold greater than the endogenous EPO. Hence, the EPO levels measured by our assay in the spiked samples were primarily from the rHuEPO present in the samples. The color of all AF samples studied was clear, i.e., without meconium or other abnormal staining.
rHuEPO (Genetics Institute, Cambridge, MA) was added to Sorenson's phosphate buffer (pH 7.4) with 5% albumin to achieve a concentration of approximately 200 mU/ml. AF and fetal plasma samples with normal endogenous EPO concentrations were prepared similarly with and without rHuEPO. AF and fetal plasma samples with elevated endogenous EPO levels were incubated without rHuEPO. Bacteriostatic concentrations of penicillin (100 U/ml) and streptomycin (100 mg/ml) were added to all samples (GibcoTM, Invitrogen Corporation, Carlsbad, CA).
Duplicate baseline aliquots of buffer with rHuEPO, and AF and plasma (with and without rHuEPO) were collected and stored at À201C. Incubations of these fluids and Sorenson's phosphate buffer were carried out in 1.5 ml microtubes (Sarstedt, Nubrecht, Germany) in a 371C waterbath. Serial aliquots were collected on days 1, 4, 7, 14 and 21 and stored at À201C until analysis. During the period of incubation, each sample was visually inspected for bacterial or fungal growth. Bacterial or fungal growth was noted in three plasma samples and one AF sample. These samples were removed from the statistical analysis. No samples of buffer had visual evidence of bacterial contamination.
EPO levels were determined by a double-antibody radioimmunoassay method, utilizing 125 I-labeled recombinant human EPO and anti-EPO antiserum. 15 This assay does not differentiate between endogenous and recombinant hormone. Samples with endogenous and recombinant EPO concentrations >50 mU/ml were diluted to enable accurate measurement of EPO within the linear portion of the standard curve. The inter-and intra-assay coefficients of variation of plasma pools were 4.9 to 11.6% and 3.2 to 7.7%, respectively. Results obtained from the first five of 27 AF samples were included in a publication by Teramo et al. 3 Statistical analyses were performed with SigmaStat version 2.0 (SPSS Inc., Chicago, IL). Kolmogorov-Smirnov tests of the raw and logarithmically transformed data revealed a non-normal distribution. Thus, data are presented as median with inner-quartile range. Within-group comparisons of the change in endogenous and recombinant EPO over time were carried out with Friedman repeated measures analysis of variance (ANOVA) using Dunnett's post hoc comparison method. Mann-Whitney rank sum test and Kruskal-Wallis one-way ANOVA supplemented with Dunn's method were used for between-group comparisons. A p value of <0.05 was considered statistically significant.
RESULTS
In all, 46 samples (27 AF and 19 plasma) were collected between December 1999 and July 2002. As can be seen in Figure 1 , the majority of the AF and plasma EPO levels were above the upper limits of normal. This is expected, as the fluids studied reflected a spectrum of fetal conditions, including pregnancies at high risk for fetal hypoxia. A statistically significant decline of both endogenous and recombinant EPO occurred in AF and fetal plasma during incubation at 371C over 21 days (Table 1 and Figure 2 ). Relative to the initial preincubation EPO levels, endogenous EPO levels declined over the 21-day incubation at similar rates in AF and fetal plasma with a median percent decline (inner-quartile range) of 68% (56%, 73%) for AF and 69% (59%, 78%) for fetal plasma.
Recombinant EPO levels remained stable in Sorenson's phosphate buffer over the 21-day incubation, with 94% (88%, 97%)
Endogenous EPO concentration, mU/mL Figure 1 . Endogenous EPO concentration in AF and fetal plasma prior to incubation at 371C. The horizontal lines at 20 mU/ml for AF and 60 mU/ml for plasma denote abnormally elevated endogenous EPO levels based on previous studies. 1,2,5 AF EPO values ranged from 5 to 3054 mU/ml (n ¼ 28) and plasma EPO values ranged from 14 to 1114 mU/ml (n ¼ 19).
of the initial concentration remaining at 21 days. Median concentrations of rHuEPO incubated in AF and plasma decreased over time with 29% (7%, 47%) of initial concentration remaining at 21 days in AF (p<0.001) and 56% (49%, 64%) of initial concentration remaining in plasma (p<0.001). rHuEPO levels declined more quickly than endogenous EPO levels in both AF and plasma ( p<0.05).
DISCUSSION
While proteins exhibit varying stability, the literature on EPO supports the observation that EPO is relatively stable. 10, 11 However, the stability of EPO in AF and plasma at 371C has only recently been addressed. 3 The results of the present study support these recent findings of statistically significant degradation of EPO at 371C in AF and plasma. Clarification of the rate of endogenous EPO decline over time at 371C facilitates accurate interpretation of EPO levels obtained following fetal demise. Endogenous EPO measured in either plasma or AF during a viable pregnancy or at delivery of a live-born infant reflects the current steady state of endogenous EPO production and clearance. With fetal demise, endogenous EPO production ceases, and as suggested in the current in vitro study, in vivo levels likely decline over time. Based on the present data, if one can estimate the duration of time elapsed between fetal demise and fluid sampling, then extrapolation back to the concentration of EPO present at the time of fetal demise is possible.
In the present study, rHuEPO was incubated in Sorenson's phosphate buffer (pH 7.4) with 5% albumin to study EPO's stability in an environment devoid of the cellular elements and degradative factors present in AF and plasma. The use of rHuEPO was necessary as it was not feasible to extract pure endogenous hormone from AF and plasma for incubation in buffer. rHuEPO offers a reasonable comparison with endogenous EPO based on its similar structure, immunoreactivity and biologic activity. 16 rHuEPO concentrations remained stable during incubation in phosphate buffer in contrast to endogenous EPO concentrations, which declined in both AF and plasma. Interestingly, rHuEPO levels declined more rapidly than endogenous EPO levels in AF and plasma ( p<0.05). Although rHuEPO has the same amino acid sequence as endogenous human EPO, it differs in its carbohydrate side chains. The more rapid decline of rHuEPO in AF and plasma compared to endogenous EPO suggests that subtle structural differences between endogenous EPO and rHuEPO may be responsible for the latter's increased susceptibility to degradation.
Receptor-mediated clearance is hypothesized to be the major mechanism of circulating EPO disappearance in vivo. 2, 17 Comparison of the rates of plasma 125 I-rHuEPO and rHuEPO clearance in vivo in newborn lambs revealed a slower clearance of Progressive decline in recombinant and endogenous EPO during incubation. Median EPO and rHuEPO concentrations significantly decline in AF and fetal plasma during incubation at 371C over 21 days. rHuEPO remains stable in buffer at 371C over 21 days.
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EPO Levels Decline in Amniotic Fluid and Plasma I-rHuEPO, suggesting that iodination-induced molecular changes resulted in reduced EPO receptor affinity and thus reduced clearance. 12 In contrast, in the present study, we observed that rHuEPO (the artificially modified hormone in this study) displayed a faster rate of degradation compared to endogenous EPO in AF and plasma. Also, isolation of plasma via centrifugation of fetal blood excluded circulating cells possessing EPO receptors. Thus, it is unlikely that receptor-mediated clearance played a major role in the present study. Instead, it seems more likely that enzymatic or other degradative processes in AF and plasma that contribute to endogenous and recombinant EPO disappearance are active at 371C. Furthermore, the in vitro rate of plasma EPO degradation observed in this study might be an underestimate of EPO decline in vivo if receptor-mediated clearance remains active following fetal demise.
Both endogenous and recombinant EPO demonstrate increasing degradation in human AF with decreasing pH. 18 Calhoun et al. 18 demonstrated a statistically significant decline of EPO in AF at 371C after 1-and 2-hour incubations at pH 3.2 and pH 4.5 with no significant change at pH 5.8. The mean pH of human AF is 7.04 (range 6.96 to 7.20) 19 and, in the animal model, pH declines rapidly following fetal demise. 15 Although the pH of study fluids was not measured before or during incubation in the present study, it is possible that the pH of the biologic fluids examined decreased during incubation, contributing to increased EPO degradation over time.
Gastrointestinal factors present in AF likely contribute to in vivo EPO inactivation and degradation. EPO is quickly degraded by incubation with proteases such as trypsin, chymotrypsin, papain and aminopeptidase. 20 Gastric enzymes such as enterokinase and pepsinogen are produced by the human fetus and have been isolated in AF as early as 26 to 28 weeks gestation. 21 While the active passage of gastric proteases to AF likely decreases following fetal demise, the in vivo environment may include a greater concentration of these factors than was represented in this in vitro study, and thus actual in vivo EPO degradation may be underestimated.
The in vitro AF incubation examining endogenous EPO stability at 371C in five uncomplicated pregnancies by Teramo et al. 3 demonstrated a linear decline in normal EPO levels over time, with 46% of the mean initial concentration remaining at 21 days. The current study, with its intent to expand on these preliminary findings, demonstrated a decline in endogenous EPO in AF, but to a lesser degree ( p ¼ 0.03), with a median of 68% of AF endogenous EPO remaining at 21 days. The reason for this discrepancy in degree of decline is not clear, but it may be a type 1 error related to small sample size. While the current study included samples with abnormally elevated endogenous EPO levels, there was not a statistically significant difference in the rate of endogenous EPO decline between samples with initial high and normal levels.
Despite its limitations, the in vitro model in this study allowed the frequent sample collection and observation over an extended period of time that is not ethically justified in vivo in humans. Some potentially important conditions present in vivo following fetal demise are lacking in our model: the interaction of the fetal membranes and altered placental permeability with potential passage of modulating EPO degradative factors from the mother to AF. The quantity of cellular debris is likely to increase following fetal demise as tissue maceration occurs. All of the AF and plasma samples tested in this study were obtained following live births, and thus do not fully represent conditions following demise. Likewise, none of our samples were meconium-stained, though the association of meconium staining with elevated AF EPO has been demonstrated by some 3, 22 but not others. 1 Based on the present study, we conclude that endogenous and recombinant EPO levels decline significantly over time at 371C in fetal plasma and AF. If the time between demise and fluid sampling is known, the expected rate of EPO decline and sensitivity of the radioimmunoassay facilitate extrapolation of a measured EPO level to the expected level at the time of demise. Thus, this study suggests that measurement of fetal endogenous EPO, whether during pregnancy or within 3 weeks of intrauterine demise, might reflect the presence or absence of chronic fetal hypoxia with elevated or normal EPO levels, respectively. Addition of this information to the other tools in current clinical use (e.g., nonstress test, biophysical profile, or postmortem exam) may have application in unexplained or unexpected fetal demise by providing a more complete understanding of fetal condition and the fetus' response to its environment in the hours and days prior to demise.
Characterization of the mechanisms of EPO degradation in AF and fetal plasma is needed. Further study of the effects of other factors commonly associated with fetal distress or intrauterine fetal demise (such as meconium or other discoloration of AF, whether by blood from placental abruption or tissue breakdown following demise) on endogenous EPO degradation is warranted. In addition, prospective evaluation of EPO stability in an animal model of fetal demise may provide a closer representation of the in vivo stability of EPO following human fetal demise.
